Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation

Expert Review of Clinical Immunology

Volumn 5, Issue 6, 2009, Pages 749-764

  Ritter, Thomas ^a   Pleyer, Uwe ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adenovirus; Cornea; Gene therapy; Immunomodulation; Retrovirus; Transplantation

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOSTATIN KRINGLE 5 FUSION PROTEIN; HERPESVIRUS VECTOR; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE COSTIMULATOR IMMUNOGLOBULIN FUSION PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 4; LENTIVIRUS VECTOR; LIPOSOME; MINOR HISTOCOMPATIBILITY ANTIGEN; NERVE GROWTH FACTOR; PARVOVIRUS VECTOR; PD1 L1 IMMUNOGLOBULIN FUSION PROTEIN; PROTEIN BCL XL; RETROVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR IMMUNOGLOBULIN FUSIO PROTEIN; UNCLASSIFIED DRUG; VIRAL MACROPHAGE INFLAMMATORY PROTEIN II;

ALLOGRAFT; CORNEA TRANSPLANTATION; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; ELECTROPORATION; GENE GUN; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 77949811286     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.59     Document Type: Review

References (154)

1. Sanfilippo F, MacQueen JM, Vaughn WK, Foulks GN. Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation. N. Engl. J. Med. 315(1), 29-35 (1986).
2. Pleyer U, Mondino BJ, Adamu SA, Pitchekian-Halabi H, Engstrom RE, Glasgow BJ. Immune response to Staphylococcus epidermidis-induced endophthalmitis in a rabbit model. Invest. Ophthalmol. Vis. Sci. 33(9), 2650-2663 (1992).
3. Reinhard T, Hutmacher M, Sundmacher R. Acute and chronic immune reactions after penetrating keratoplasty with normal immune risk. Klin. Monatsbl. Augenheilkd. 210(3), 139-143 (1997).
4. George AJ, Larkin DF. Corneal transplantation: the forgotten graft. Am. J. Transplant. 4(5), 678-685 (2004).
5. Pleyer U, Ritter T. Gene therapy in immune-mediated diseases of the eye. Prog. Retin. Eye Res. 22(3), 277-293 (2003).
6. Klebe S, Coster DJ, Williams KA. Rejection and acceptance of corneal allografts. Curr. Opin. Organ Transplant. 14(1), 4-9 (2009).
7. Pleyer U, Milani JK, Dukes A et al. Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest. Ophthalmol. Vis. Sci. 36(1), 52-61 (1995).
8. He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest. Ophthalmol. Vis. Sci. 32(10), 2723-2728 (1991).
9. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 80(5), 555-563 (2005).
10. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13(2), 559-575 (2002).
11. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278(3), 1910-1914 (2003).
12. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9(8), 589-593 (2000).
13. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1), 65-70 (2003).
14. Luger D, Silver PB, Tang J et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205(4), 799-810 (2008).
15. Chen Y, Wood KJ. Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection? Transplantation 84(9), 1071-1074 (2007).
16. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 148(1), 32-46 (2007).
17. Illigens BM, Yamada A, Fedoseyeva EV et al. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum. Immunol. 63(10), 912-925 (2002).
18. Sano Y, Ksander BR, Streilein JW. Minor H, rather than MHC, alloantigens offer the greater barrier to successful orthotopic corneal transplantation in mice. Transpl. Immunol. 4(1), 53-56 (1996).
19. Boisgerault F, Liu Y, Anosova N, Ehrlich E, Dana MR, Benichou G. Role of CD4+ and CD8+ T cells in allorecognition: lessons from corneal transplantation. J. Immunol. 167(4), 1891-1899 (2001).
20. Huq S, Liu Y, Benichou G, Dana MR. Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment. J. Immunol. 173(7), 4464-4469 (2004).
21. Herrera OB, Golshayan D, Tibbott R et al. A novel pathway of alloantigen presentation by dendritic cells. J. Immunol. 173(8), 4828-4837 (2004).
22. Gokmen MR, Lombardi G, Lechler RI. The importance of the indirect pathway of allorecognition in clinical transplantation. Curr. Opin. Immunol. 20(5), 568-574 (2008).
23. Waldmann H, Graca L, Adams E, Fairchild P, Cobbold S. Regulatory T cells in transplantation tolerance. Curr. Top. Microbiol. Immunol. 293, 249-264 (2005).
24. Akl A, Luo S, Wood KJ. Induction of transplantation tolerance - the potential of regulatory T cells. Transpl. Immunol. 14(3-4), 225-230 (2005).
25. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3(3), 199-210 (2003).
26. Pearson TC, Madsen JC, Larsen CP, Morris PJ, Wood KJ. Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody. Transplantation 54(3), 475-483 (1992).
27. Binder J, Lehmann M, Graser E et al. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation 61(5), 804-811 (1996).
28. Siegling A, Lehmann M, Riedel H et al. A nondepleting anti-rat CD4 monoclonal antibody that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts. Transplantation 57(3), 464-467 (1994).
29. Alters SE, Shizuru JA, Ackerman J, Grossman D, Seydel KB, Fathman CG. Anti-CD4 mediates clonal anergy during transplantation tolerance induction. J. Exp. Med. 173(2), 491-494 (1991).
30. Cobbold SP, Martin G, Waldmann H. The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur. J. Immunol. 20(12), 2747-2755 (1990).
31. Qin S, Cobbold SP, Pope H et al. Infectious transplantation tolerance. Science 259(5097), 974-977 (1993).
32. Onodera K, Volk HD, Ritter T, Kupiec-Weglinski JW. Thymus requirement and antigen dependency in the infectious tolerance pathway in transplant recipients. J. Immunol. 160(12), 5765-5772 (1998).
33. Zhai Y, Shen XD, Lehmann M, Busuttil R, Volk HD, Kupiec-Weglinski JW. T cell subsets and in vitro immune regulation in infectious transplantation tolerance. J. Immunol. 167(9), 4814-4820 (2001).
34. Onodera K, Lehmann M, Akalin E, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Induction of infectious tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J. Immunol. 157(5), 1944-1950 (1996).
35. Hara M, Kingsley CI, Niimi M et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 166(6), 3789-3796 (2001).
36. Bertelmann E, Reinhard T, Pleyer U. Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society. Ophthalmologe 100(12), 1031-1035 (2003).
37. Price FW Jr, Price DA, Ngakeng V, Price MO. Survey of steroid usage patterns during and after low-risk penetrating keratoplasty. Cornea 28(8), 865-870 (2009).
38. Bainbridge JW, Smith AJ, Barker SS et al. Effect of gene therapy on visual function in Lebers congenital amaurosis. N. Engl. J. Med. 358(21), 2231-2239 (2008).
39. Maguire AM, Simonelli F, Pierce EA et al. Safety and efficacy of gene transfer for Lebers congenital amaurosis. N. Engl. J. Med. 358(21), 2240-2248 (2008).
40. Hauswirth W, Aleman TS, Kaushal S et al. Phase I trial of Leber congenital amaurosis due to rpe65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results. Hum. Gene Ther. (2008) (Epub ahead of print).
41. Jun AS, Larkin DF. Prospects for gene therapy in corneal disease. Eye 17(8), 906-911 (2003).
42. Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am. J. Ophthalmol. 140(6), 1112-1122 (2005).
43. Mohan RR, Schultz GS, Hong JW, Mohan RR, Wilson SE. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp. Eye Res. 76(3), 373-383 (2003).
44. Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV. Corneal gene therapy. J. Control Release 124(3), 107-133 (2007).
45. Fu H, Larkin DF, George AJ. Immune modulation in corneal transplantation. Transplant Rev. (Orlando) 22(2), 105-115 (2008).
46. Parker DG, Brereton HM, Coster DJ, Williams KA. The potential of viral vector-mediated gene transfer to prolong corneal allograft survival. Curr. Gene Ther. 9(1), 33-44 (2009).
47. Gong N, Pleyer U, Yang J et al. Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J. Gene Med. 8(4), 459-467 (2006).
48. Klebe S, Coster DJ, Sykes PJ et al. Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J. Immunol. 175(4), 2219-2226 (2005).
49. Pleyer U, Bertelmann E, Rieck P, Hartmann C, Volk HD, Ritter T. Survival of corneal allografts following adenovirusmediated gene transfer of interleukin-4. Graefes Arch. Clin. Exp. Ophthalmol. 238(6), 531-536 (2000).
50. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 71(9), 1214-1220 (2001).
51. Larkin DF, Oral HB, Ring CJ, Lemoine NR, George AJ. Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 61(3), 363-370 (1996).
52. Mathieu P, Chauveau C, Bouchet D, Guillot C, Tesson L, Anegon I. Genetic engineering in allotransplantation of vascularized organs. Curr. Gene Ther. 2(1), 9-21 (2002).
53. Giannoukakis N, Thomson A, Robbins P. Gene therapy in transplantation. Gene Ther. 6(9), 1499-1511 (1999).
54. Pleyer U, Ritter T, Volk HD. Immune tolerance and gene therapy in transplantation. Immunol. Today 21(1), 12-14 (2000).
55. Ritter T, Vogt K, Rieck P et al. Adenovirusmediated gene transfer of interleukin-4 to corneal endothelial cells and organ cultured corneas leads to high IL-4 expression. Exp. Eye Res. 69(5), 563-568 (1999).
56. Oral HB, Larkin DF, Fehervari Z et al. Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Gene Ther. 4(7), 639-647 (1997).
57. Mohan RR, Sharma A, Netto MV, Sinha S, Wilson SE. Gene therapy in the cornea. Prog. Retin. Eye Res. 24(5), 537-559 (2005).
58. Konig Merediz SA, Zhang EP, Wittig B, Hoffmann F. Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch. Clin. Exp. Ophthalmol. 238(8), 701-707 (2000).
59. Gong N, Pleyer U, Volk HD, Ritter T. Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival. Gene Ther. 14(6), 484-490 (2007).
60. Pillai RG, Beutelspacher SC, Larkin DF, George AJ. Expression of the chemokine antagonist vMIP II using a non-viral vector can prolong corneal allograft survival. Transplantation 85(11), 1640-1647 (2008).
61. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7(1), 33-40 (2001).
62. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 60(2), 249-271 (2000).
63. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004 - an overview. J. Gene Med. 6(6), 597-602 (2004).
64. Graham FL. Adenovirus vectors for high-efficiency gene transfer into mammalian cells. Immunol. Today 21(9), 426-428 (2000).
65. Ritter T, Lehmann M, Volk HD. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs 16(1), 3-10 (2002).
66. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lungdirected gene therapy with recombinant adenoviruses. J. Virol. 69(4), 2004-2015 (1995).
67. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J. Clin. Invest. 105(9), 1169-1172 (2000).
68. Cao L, Kulmburg P, Veelken H et al. Cytokine gene transfer in cancer therapy. Stem Cells 16(Suppl. 1), 251-260 (1998).
69. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J. Natl Cancer Inst. 89(1), 21-39 (1997).
70. Campochiaro PA, Nguyen QD, Shah SM et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum. Gene Ther. 17(2), 167-176 (2006).
71. Abraham NG, da Silva JL, Lavrovsky Y et al. Adenovirus-mediated heme oxygenase-1 gene transfer into rabbit ocular tissues. Invest. Ophthalmol. Vis. Sci. 36(11), 2202-2210 (1995).
72. Qian Y, Leong FL, Kazlauskas A, Dana MR. Ex vivo adenovirus-mediated gene transfer to corneal graft endothelial cells in mice. Invest. Ophthalmol. Vis. Sci. 45(7), 2187-2193 (2004).
73. Liu J, Saghizadeh M, Tuli SS et al. Different tropism of adenoviruses and adeno-associated viruses to corneal cells: implications for corneal gene therapy. Mol. Vis. 14, 2087-2096 (2008).
74. Beutelspacher SC, Ardjomand N, Tan PH et al. Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction. Exp. Eye Res. 80(6), 787-794 (2005).
75. Hudde T, Rayner SA, De Alwis M et al. Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium. Cornea 19(3), 369-373 (2000).
76. Beutelspacher SC, Pillai R, Watson MP et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur. J. Immunol. 36(3), 690-700 (2006).
77. Kay MA, Manno CS, Ragni MV et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24(3), 257-261 (2000).
78. Stedman H, Wilson JM, Finke R, Kleckner AL, Mendell J. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: a-, b-, g-, or d-sarcoglycan gene delivered with intramuscular instillations of adenoassociated vectors. Hum. Gene Ther. 11(5), 777-790 (2000).
79. Wagner JA, Messner AH, Moran ML et al. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109(2 Pt 1), 266-274 (1999).
80. Li Q, Miller R, Han PY et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol. Vis. 14, 1760-1769 (2008).
81. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther. 10(11), 977-982 (2003).
82. Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum. Gene Ther. 17(3), 253-263 (2006).
83. Jenkins MK, Pardoll DM, Mizuguchi J, Quill H, Schwartz RH. T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol. Rev. 95, 113-135 (1987).
84. Najafian N, Sayegh MH. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Investig. Drugs 9(9), 2147-2157 (2000).
85. Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196, 85-108 (2003).
86. Levisetti MG, Padrid PA, Szot GL et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159(11), 5187-5191 (1997).
87. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94(16), 8789-8794 (1997).
88. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3), 443-453 (2005).
89. Thiel MA, Steiger JU, OConnell PJ, Lehnert AM, Coster DJ, Williams KA. Local or short-term systemic costimulatory molecule blockade prolongs rat corneal allograft survival. Clin. Experiment. Ophthalmol. 33(2), 176-180 (2005).
90. Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 43(4), 1095-1103 (2002).
91. Miao G, Ito T, Uchikoshi F et al. Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. Transplantation 78(1), 59-64 (2004).
92. Wei L, Wei-Min L, Cheng G, Bao-Guo Z. Upregulation of CD4+CD25+ T lymphocyte by adenovirus-mediated gene transfer of CTLA4Ig fusion protein in experimental autoimmune myocarditis. Autoimmunity 39(4), 289-298 (2006).
93. Lin H, Rathmell JC, Gray GS, Thompson CB, Leiden JM, Alegre ML. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J. Exp. Med. 188(1), 199-204 (1998).
94. Ardjomand N, McAlister JC, Rogers NJ, Tan PH, George AJ, Larkin DF. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection. Invest. Ophthalmol. Vis. Sci. 44(9), 3899-3905 (2003).
95. Hutloff A, Dittrich AM, Beier KC et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397(6716), 263-266 (1999).
96. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29-53 (2002).
97. Rottman JB, Smith T, Tonra JR et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat. Immunol. 2(7), 605-611 (2001).
98. Harada H, Salama AD, Sho M et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J. Clin. Invest. 112(2), 234-243 (2003).
99. Fabian D, Gong N, Vogt K, Volk HD, Pleyer U, Ritter T. The influence of inducible costimulator fusion protein (ICOSIg) gene transfer on corneal allograft survival. Graefes Arch. Clin. Exp. Ophthalmol. 245(10), 1515-1521 (2007).
100. Watson MP, George AJ, Larkin DF. Differential effects of costimulatory pathway modulation on corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 47(8), 3417-3422 (2006).
101. Li XL, Menoret S, Le Mauff B, Angin M, Anegon I. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Transplantation 86(1), 10-15 (2008).
102. Hori J, Wang M, Miyashita M et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J. Immunol. 177(9), 5928-5935 (2006).
103. Shen L, Jin Y, Freeman GJ, Sharpe AH, Dana MR. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J. Immunol. 179(6), 3672-3679 (2007).
104. Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp. Eye Res. 79(5), 677-688 (2004).
105. You L, Kruse FE, Volcker HE. Neurotrophic factors in the human cornea. Invest. Ophthalmol. Vis. Sci. 41(3), 692-702 (2000).
106. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24, 677-736 (2001).
107. Ramer-Quinn DS, Baker RA, Sanders VM. Activated T helper 1 and T helper 2 cells differentially express the b-2- adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production. J. Immunol. 159(10), 4857-4867 (1997).
108. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE. Differential expression of the b2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J. Immunol. 158(9), 4200-4210 (1997).
109. Gong N, Pleyer U, Vogt K et al. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest. Ophthalmol. Vis. Sci. 48(3), 1043-1052 (2007).
110. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248(4960), 1230-1234 (1990).
111. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 b in mediating the production of IL-8 triggered by lipopolysaccharide. J. Exp. Med. 178(6), 2207-2211 (1993).
112. Ralph P, Nakoinz I, Sampson-Johannes A et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J. Immunol. 148(3), 808-814 (1992).
113. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174(4), 915-924 (1991).
114. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174(5), 1209-1220 (1991).
115. Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg JS. A single amino acid determines the immunostimulatory activity of interleukin 10. J. Exp. Med. 191(2), 213-224 (2000).
116. Qin L, Ding Y, Pahud DR, Robson ND, Shaked A, Bromberg JS. Adenovirusmediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum. Gene Ther. 8(11), 1365-1374 (1997).
117. DeBruyne LA, Li K, Chan SY, Qin L, Bishop DK, Bromberg JS. Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther. 5(8), 1079-1087 (1998).
118. Brauner R, Wu L, Laks H et al. Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts: method and efficacy of adenovirus-mediated transduction. J. Thorac. Cardiovasc. Surg. 113(6), 1059-1066; discussion 1066-11057 (1997).
119. David A, Chetritt J, Guillot C et al. Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats. Gene Ther. 7(6), 505-510 (2000).
120. Beauregard C, Stevens C, Mayhew E, Niederkorn JY. Cutting edge: atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection. J. Immunol. 174(11), 6577-6581 (2005).
121. Flynn TH, Ohbayashi M, Ikeda Y, Ono SJ, Larkin DF. Effect of allergic conjunctival inflammation on the allogeneic response to donor cornea. Invest. Ophthalmol. Vis. Sci. 48(9), 4044-4049 (2007).
122. Niederkorn JY, Chen PW, Mellon J, Stevens C, Mayhew E. Allergic airway hyperreactivity increases the risk for corneal allograft rejection. Am. J. Transplant. 9(5), 1017-1026 (2009).
123. Gately MK, Desai BB, Wolitzky AG et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 147(3), 874-882 (1991).
124. King WJ, Comer RM, Hudde T, Larkin DF, George AJ. Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 70(8), 1225-1233 (2000).
125. Liu Y, Dana MR, Tewari V, Taylor AW. Immune response to intragraft antigen in draining lymph nodes after corneal transplantation is mediated by interleukin-12. J. Interferon Cytokine Res. 21(10), 813-819 (2001).
126. Gillessen S, Carvajal D, Ling P et al. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur. J. Immunol. 25(1), 200-206 (1995).
127. Ritter T, Yang J, Dannowski H, Vogt K, Volk HD, Pleyer U. Effects of interleukin- 12p40 gene transfer on rat corneal allograft survival. Transpl. Immunol. 18(2), 101-107 (2007).
128. Cai Q, Rubin JT, Lotze MT. Genetically marking human cells - results of the first clinical gene transfer studies. Cancer Gene Ther. 2(2), 125-136 (1995).
129. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol. Rev. 196, 125-146 (2003).
130. Coates PT, Thomson AW. Dendritic cells, tolerance induction and transplant outcome. Am. J. Transplant. 2(4), 299-307 (2002).
131. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2(3), 151-161 (2002).
132. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation - friend or foe? Immunity 14(4), 357-368 (2001).
133. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol. 7(8), 610-621 (2007).
134. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 66(12), 1567-1574 (1998).
135. Takayama T, Morelli AE, Robbins PD, Tahara H, Thomson AW. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther. 7(15), 1265-1273 (2000).
136. Takayama T, Kaneko K, Morelli AE, Li W, Tahara H, Thomson AW. Retroviral delivery of transforming growth factor-b1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. Transplantation 74(1), 112-119 (2002).
137. Jiang HR, Muckersie E, Robertson M, Forrester JV. Antigen-specific inhibition of experimental autoimmune uveoretinitis by bone marrow-derived immature dendritic cells. Invest. Ophthalmol. Vis. Sci. 44(4), 1598-1607 (2003).
138. Usui Y, Takeuchi M, Hattori T et al. Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice. Arch. Ophthalmol. 127(4), 514-519 (2009).
139. Groux H, OGarra A, Bigler M et al. A CD4+ T-cell subset inhibits antigenspecific T-cell responses and prevents colitis. Nature 389(6652), 737-742 (1997).
140. Feng G, Chan T, Wood KJ, Bushell A. Donor reactive regulatory T cells. Curr. Opin. Organ Transplant. 14(4), 432-438 (2009).
141. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609), 1057-1061 (2003).
142. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf ) mutant mouse. Am. J. Pathol. 138(6), 1379-1387 (1991).
143. Blair PJ, Bultman SJ, Haas JC, Rouse BT, Wilkinson JE, Godfrey VL. CD4+CD8- T cells are the effector cells in disease pathogenesis in the scurfy (sf ) mouse. J. Immunol. 153(8), 3764-3774 (1994).
144. Clark LB, Appleby MW, Brunkow ME, Wilkinson JE, Ziegler SF, Ramsdell F. Cellular and molecular characterization of the scurfy mouse mutant. J. Immunol. 162(5), 2546-2554 (1999).
145. Zahorsky-Reeves JL, Wilkinson JE. The murine mutation scurfy (sf ) results in an antigen-dependent lymphoproliferative disease with altered T cell sensitivity. Eur. J. Immunol. 31(1), 196-204 (2001).
146. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 39(8), 537-545 (2002).
147. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 109(2), 827-835 (2007).
148. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and b-galactosidase. Proc. Natl Acad. Sci. USA 93(12), 5731-5736 (1996).
149. Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol. Ther. 8(5), 846-852 (2003).
150. Barcia C, Jimenez-Dalmaroni M, Kroeger KM et al. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol. Ther. 15(12), 2154-2163 (2007).
151. Yanez-Munoz RJ, Balaggan KS, MacNeil A et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12(3), 348-353 (2006).
152. Rayner SA, Larkin DF, George AJ. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest. Ophthalmol. Vis. Sci. 42(7), 1568-1573 (2001).
153. Jessup CF, Brereton HM, Sykes PJ, Thiel MA, Coster DJ, Williams KA. Local gene transfer to modulate rat corneal allograft rejection. Invest. Ophthalmol. Vis. Sci. 46(5), 1675-1681 (2005).
154. Murthy RC, McFarland TJ, Yoken J et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest. Ophthalmol. Vis. Sci. 44(5), 1837-1842 (2003).